Fonte: Molecular Therapy Oncology. Unidades: ICB, FM
Assuntos: IMUNOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, GENÉTICA, ADENOVÍRUS, SARCOMA, NEOPLASIAS POR TIPO HISTOLÓGICO, INTERFERONS, MELANOMA, MACRÓFAGOS
ABNT
DOMINGUES, Ana Carolina Martins et al. Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade. Molecular Therapy Oncology, v. 33, n. 1, p. 12 , 2025Tradução . . Disponível em: https://doi.org/10.1016/j.omton.2025.200942. Acesso em: 08 out. 2025.APA
Domingues, A. C. M., Oliveira, S. B. de, Tessarollo, N. G., Lepique, A. P., Rodrigues, O. A., Sharova, T., et al. (2025). Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade. Molecular Therapy Oncology, 33( 1), 12 . doi:10.1016/j.omton.2025.200942NLM
Domingues ACM, Oliveira SB de, Tessarollo NG, Lepique AP, Rodrigues OA, Sharova T, Lawless A, Li D, Basnet M, Boland GM, Cohen S, Jenkins RW, Strauss BE. Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade [Internet]. Molecular Therapy Oncology. 2025 ; 33( 1): 12 .[citado 2025 out. 08 ] Available from: https://doi.org/10.1016/j.omton.2025.200942Vancouver
Domingues ACM, Oliveira SB de, Tessarollo NG, Lepique AP, Rodrigues OA, Sharova T, Lawless A, Li D, Basnet M, Boland GM, Cohen S, Jenkins RW, Strauss BE. Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade [Internet]. Molecular Therapy Oncology. 2025 ; 33( 1): 12 .[citado 2025 out. 08 ] Available from: https://doi.org/10.1016/j.omton.2025.200942